Transition hands over Alzheimer's asset to Elan ahead of Phase III
This article was originally published in Scrip
Executive Summary
Transition Therapeutics has relinquished its 30% stake in the Alzheimer's disease asset ELND005 to partner Elan, along with responsibility for the costs associated with its clinical development, in return for a modified milestone payment structure and royalties on potential future sales.